News | July 13, 2010

New Study Shows Women Have Lower Survival Benefits from ICD Therapy

July 13, 2010 – A new meta-analysis of five implantable cardioverter-defibrillator (ICD) studies shows a smaller impact of sudden cardiac death (SCD) on overall mortality in women. According to research published in the July edition of the HeartRhythm Journal, the official journal of the Heart Rhythm Society, women in primary prevention ICD trials have the same overall mortality as men, while experiencing significantly less appropriate ICD interventions. With more than 1,600 women, this meta-analysis includes the largest cohort of women to date.

The study was designed to evaluate primary prevention ICD trials that assessed gender differences with the end points of total mortality, appropriate ICD interventions and survival benefits compared to placebo. The meta-analysis study included 7,229 patients, 22 percent women, with dilated cardiomyopathy enrolled in five different studies: MADIT-II, MUSTT, SCD-HeFT, DEFINITE and COMPANION. To ensure direct comparisons between women and men, analysis for each study was adjusted for the maximum number of confounding factors and covariates in order to provide approximations that would be affected the least by standard gender differences.

Overall study findings revealed women had the same overall mortality as men. However, women experienced significantly less ICD interventions on rapid sustained ventricular tachycardia or fibrillation than men, suggesting that women are less likely to suffer from SCD. Additionally, among men ICD therapy was associated with a 33 percent reduction of total mortality compared to the placebo group while women had a smaller and nonsignificant reduction of mortality.

“Our main focus was to compare women to men when it came to clinical outcomes following prophylactic ICD placement to determine if certain subgroups of patients should be treated differently,” said lead author Pasquale Santangeli of the Cardiology Department at Catholic University in Rome, Italy. “We believe that our findings may explain why women have a smaller and nonsignificant survival benefits from prophylactic ICD therapy and the importance for further studies to be done on this underrepresented subgroup – women.”

Many studies previously conducted have underrepresented women in primary prevention ICD trials, and this study demonstrates that women do benefit differently from ICD therapies than men. Therefore, the study suggests that women should be considered more often in trials to continue discoveries for the best outcomes and preventative measures for each gender.

For more information: www.heartrhythmjournal.com

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init